Opinion|Videos|January 7, 2025
Systemic Review/Meta-Analysis From ASH 2024
Panelists discuss how adding a fourth drug (daratumumab) to standard triplet induction therapy may improve outcomes for patients with newly diagnosed, transplant-eligible multiple myeloma.
Advertisement
Advertisement
Related to this article
Elranatamab reduced the risk of disease progression or death vs standard care in patients with R/R myeloma after prior anti-CD38 therapy and lenalidomide.
Etentamig, a BCMAxCD3 bispecific antibody, was submitted for potential FDA approval based on the phase 3 CERVINO trial in relapsed/refractory multiple myeloma.
Advertisement
Advertisement
Trending on Targeted Onc
1
A New Era in Sarcoma Treatment? Dr Banks on the Potential of TIL Therapy
2
FDA Finalizes Potency Guidance for Cell and Gene Therapy Products
3
FDA Approves Generic Venetoclax Tablets for CLL/SLL and AML
4
Enzalutamide Fails to Improve Survival in High-Risk Prostate Cancer
5